George A. O'Brien

"Misleading" To Suggest A Biosimilar Is Inferior, FDA Draft Guidance Warns

FDA Issues Draft Guidance Regarding "Sameness" For Orphan Drug Gene Therapies

FDA Publishes Final Guidance On ANDA/505(B)(2) NDA Pathways